Hemophilus (e.g., Hemophilus Influenzae, Hemophilus Gallinarum, Hemophilus Pleuropnemoniae, Etc.) Patents (Class 424/256.1)
-
Patent number: 8277821Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: GrantFiled: April 21, 2011Date of Patent: October 2, 2012Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Publication number: 20120244182Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventor: Nicholas M. VALIANTE
-
Publication number: 20120237544Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.Type: ApplicationFiled: September 21, 2010Publication date: September 20, 2012Applicant: Royal Holloway and Bedford New CollegeInventors: Simon Michael Cutting, Hong Anh Huynh
-
Patent number: 8263363Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.Type: GrantFiled: October 5, 2010Date of Patent: September 11, 2012Assignee: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr.
-
Publication number: 20120225091Abstract: The present invention is a live vaccine from a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth. Several SNPs have been identified as associated with specific proteins that are associated with virulence as seen in the literature in H. parasuis or related bacterial species.Type: ApplicationFiled: February 13, 2012Publication date: September 6, 2012Applicant: Newport Laboratories, Inc.Inventors: Kamesh R. Sirigireddy, Paulraj K. Lawrence, Russell F. Bey, Randy R. Simonson
-
Publication number: 20120195937Abstract: The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.Type: ApplicationFiled: February 15, 2012Publication date: August 2, 2012Inventors: Nathalie Marie-Josephe GARCON, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
-
Publication number: 20120171244Abstract: Mucosal immunization using one or more antigens following parenteral administration of the same or different antigens is described.Type: ApplicationFiled: February 4, 2012Publication date: July 5, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventor: Derek O'Hagan
-
Publication number: 20120093868Abstract: Polypeptides comprising various amino acid sequences derived from Haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis. They may also be useful for diagnostic purposes, and as targets for antibiotics. Antibodies against the polypeptides are also disclosed, as are the coding nucleic acids.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Vega MASIGNANI, Rino Rappuoli, Herve Tettelin
-
Patent number: 8137681Abstract: The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of H. influenzae B (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG—poly-L-glutamic acid) to the composition.Type: GrantFiled: May 24, 2010Date of Patent: March 20, 2012Assignee: Glaxosmithkline Biologicals, S.A.Inventors: Nathalie Marie-Josephe Garcon, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
-
Patent number: 8124098Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.Type: GrantFiled: May 25, 2010Date of Patent: February 28, 2012Assignee: Novartis Vaccines and Diagnostics SRLInventors: Vega Masignani, Beatrice Maria Arico
-
Publication number: 20120045457Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.Type: ApplicationFiled: February 15, 2010Publication date: February 23, 2012Applicant: INTERCELL AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz
-
Publication number: 20120020979Abstract: This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.Type: ApplicationFiled: April 1, 2010Publication date: January 26, 2012Applicant: CORNELL UNIVERSITYInventors: Andrea Cerutti, Kang Chen
-
Publication number: 20120003277Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Tarek Hamouda, Susan M. Ciotti
-
Patent number: 8084235Abstract: The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt.Type: GrantFiled: March 11, 2004Date of Patent: December 27, 2011Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Biemans, Karine Goraj, Emmanuel Mertens, Annick Vandercammen
-
Publication number: 20110300179Abstract: The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic.Type: ApplicationFiled: November 12, 2007Publication date: December 8, 2011Inventors: Anna-Lena Spetz-Holmgren, Ulrika Johansson, Jan Andersson, Lilian Walther-Jallow
-
Publication number: 20110293723Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
-
Publication number: 20110223174Abstract: The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of Haemophilus influenzae (NTHi). The invention also relates to the NTHi sap operon genes and the polypeptides encoded by these polynucleotide sequences. The invention also relates to a novel 110 kDa NTHi outer membrane protein and the polynucleotide that encodes this outer membrane protein. Methods of screening for NTHi infection, and treating and preventing NTHi related disorders are also contemplated.Type: ApplicationFiled: March 7, 2011Publication date: September 15, 2011Applicant: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, JR.
-
Patent number: 8007818Abstract: The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of H. influenzae B (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG-poly-L-glutamic acid) to the composition.Type: GrantFiled: June 14, 2004Date of Patent: August 30, 2011Assignee: GlaxoSmithKline Biologicals, S.R.Inventors: Nathalie Marie-Josephe Garcon, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
-
Publication number: 20110206765Abstract: Provided are non-typeable Haemophilus influenzae vaccines useful for the treatment of chronic obstructive pulmonary disease and asthma in a patient. In certain aspects, the vaccine is a monobacterial vaccine. Bacterial strains for use in the vaccines of the present application are also provided.Type: ApplicationFiled: September 17, 2009Publication date: August 25, 2011Applicant: Hunter Immunology LimitedInventors: Margaret Lorraine Dunkley, Robert Llewellyn Clancy
-
Publication number: 20110200616Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: April 21, 2011Publication date: August 18, 2011Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
-
Patent number: 7998490Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: GrantFiled: August 20, 2010Date of Patent: August 16, 2011Assignees: Nationwide Children's Hospital, Inc., The Board of Regents of University of OklahomaInventors: Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
-
Publication number: 20110159030Abstract: A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune response against Neisseria meningitidis; and (c) an antigen which induces an immune response against Streptococcus pneumoniae. The combination allows a single dose for immunising against three separate causes of a common disease, namely bacterial meningitis.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Inventor: Derek O'Hagan
-
Publication number: 20110142881Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.Type: ApplicationFiled: May 7, 2008Publication date: June 16, 2011Applicant: Alba Therapeutics CorporationInventors: Dorothea Sesardic, Blake Paterson
-
Patent number: 7943125Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.Type: GrantFiled: October 7, 2008Date of Patent: May 17, 2011Assignee: Merial LimitedInventors: Helen Rachel Crooke, Jacqueline Elizabeth Shea, Robert Graham Feldman, Sylvain Gabriel Goutebroze, Francois-Xavier Le Gros
-
Patent number: 7943150Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions, including inducing the production of antibody in an animal.Type: GrantFiled: April 11, 2008Date of Patent: May 17, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 7943151Abstract: The present invention provides compositions including siderophore receptor polypeptides from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions, including inducing the production of antibody in an animal.Type: GrantFiled: February 26, 2009Date of Patent: May 17, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Publication number: 20110104207Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.Type: ApplicationFiled: April 16, 2010Publication date: May 5, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Paul CHARIFSON, David DEININGER, Joseph DRUMM, Anne-Laure GRILLOT, Yusheng LIAO, Patricia OLIVER-SHAFFER, Dean STAMOS
-
Publication number: 20110081357Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.Type: ApplicationFiled: October 5, 2010Publication date: April 7, 2011Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: LAUREN O. BAKALETZ, ROBERT S. MUNSON, JR.
-
Patent number: 7901692Abstract: The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of Haemophilus influenzae (NTHi). The invention also relates to the NTHi sap operon genes and the polypeptides encoded by these polynucleotide sequences. The invention also relates to a novel 110 kDa NTHi outer membrane protein and the polynucleotide that encodes this outer membrane protein. Methods of screening for NTHi infection, and treating and preventing NTHi related disorders are also contemplated.Type: GrantFiled: April 15, 2010Date of Patent: March 8, 2011Assignee: Nationalwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr.
-
Patent number: 7893237Abstract: The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.Type: GrantFiled: January 7, 2008Date of Patent: February 22, 2011Assignee: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr.
-
Publication number: 20110014237Abstract: The present invention pertains to the use of Haemophilus parasuis serotype 5 bacteria in the manufacture of a vaccine for administration to a pregnant sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt after she has farrowed, against a disorder arising from Haemophilus parasuis serotype 4 bacteria. The invention also pertains to Haemophilus parasuis serotype 5 bacteria for use in the manufacture of such a vaccine.Type: ApplicationFiled: March 25, 2009Publication date: January 20, 2011Inventors: Ruud Philip Antoon Maria Segers, Maarten Hendrik Witvliet, Selma Marianne Hensen
-
Patent number: 7858073Abstract: There is described a method for selecting microbial isolates for use in oral killed vaccines against abnormal microbial colonization of mucosal surfaces by the microbes. The method comprises evaluating capacity of a plurality of different isolates of a microbe to activate antigen responsive cells to provide activation data for each microbial isolate, and the effectiveness of the isolates in reducing infection of a mucosal surface by the microbe to provide clearance data for each microbial isolate. An isolate, the activation data and clearance data for which correlate and is optimal for generating mucosal immunity against the microbe compared to the, or each, other of the isolates, or an isolate the activation data for which is optimal and a further isolate the clearance data for which is optimal, compared to the, or each, other of the isolates, respectively, is then selected for use in the vaccine.Type: GrantFiled: August 17, 2005Date of Patent: December 28, 2010Assignee: Hunter Technology LimitedInventors: Robert Clancy, Phillip Comans, Gerald Pang
-
Publication number: 20100310569Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: ApplicationFiled: August 20, 2010Publication date: December 9, 2010Applicants: NATIONWIDE CHILDREN'S HOSPITAL INC., THE BOARD OF REGENTS OF UNIVERSITY OF OKLAHOMAInventors: Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
-
Patent number: 7838003Abstract: The invention provides BASB205 polypeptides and polynucleotides encoding BASB205 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: October 5, 2001Date of Patent: November 23, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Joelle Thonnard
-
Publication number: 20100285064Abstract: The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.Type: ApplicationFiled: May 5, 2010Publication date: November 11, 2010Applicant: SERUM INSTITUTE OF INDIA LTD.Inventors: Suresh Sakharam Jadhav, Bhushan Patwardhan, Manish Gautam
-
Publication number: 20100285070Abstract: The present invention relates to Haemophilus parasuis polynucleotides produced by recombinant technology. It also relates to polypeptides that are expressed by said polynucleotides and also to a vaccine against H. parasuis that comprises said polypeptides. In another aspect, the invention also relates to the use of polynucleotides to determine if a strain of H. parasuis is virulent or avirulent.Type: ApplicationFiled: September 15, 2006Publication date: November 11, 2010Applicant: LABORATORIOS HIPRA, S.A.Inventors: Albert Bensaid, Sonia Pina Pedrero, Raquel Rivas Adan, Simone Oliveira, Enric Espuña Maso, Carmen Herrero Molina
-
Publication number: 20100272758Abstract: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.Type: ApplicationFiled: January 19, 2007Publication date: October 28, 2010Applicant: Regents of the University of MichiganInventors: Ronald Wesley Woodard, Timothy Charles Meredith, Parag Aggarwal
-
Patent number: 7811590Abstract: This invention relates to recombinant bacterial outer membrane proteins comprising one or more LB1(f) peptides from surface-exposed loop 3 of MOMP P5 of non-typeable H. influenzae. Polynucleotides encoding these recombinant proteins are also covered. The invention also relates to a method of isolating the recombinant proteins and a vaccine composition for use in the treatment of Haemophilus influenzae infection.Type: GrantFiled: December 20, 2007Date of Patent: October 12, 2010Assignees: The Ohio State University Research Foundation, GlaxoSmithKlineInventors: Lauren O. Bakaletz, Francois-Xavier Jacques Berthet, Philippe Denoel, Jan Poolman, Joelle Thonnard
-
Patent number: 7811591Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.Type: GrantFiled: July 5, 2006Date of Patent: October 12, 2010Assignee: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr.
-
Publication number: 20100255035Abstract: The present invention is a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs as a live vaccine. The present invention is also a method of preparing the cell culture, a method of preparing a vaccine from the cell culture, and a live vaccine based on the cell culture. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth.Type: ApplicationFiled: December 28, 2006Publication date: October 7, 2010Applicant: Newport Laboratories, Inc.Inventors: Simone R. Oliveira, Randy R. Simonson, Jonathan D. Mahlberg, Mark D. Titus, Tracy A. Oleson
-
Publication number: 20100233201Abstract: The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of H. influenzae B (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG—poly-L-glutamic acid) to the composition.Type: ApplicationFiled: May 24, 2010Publication date: September 16, 2010Inventors: NATHALIE MARIE-JOSEPHE GARCON, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
-
Patent number: 7785609Abstract: Recombinant production of Hia protein, in full-length and N-terminally truncated forms, of non-typeable strains of Haemophilus influenzae, is described. The nucleic acid and deduced amino acid sequences of Hia genes of various strains of non-typeable and type c Haemophilus influenzae also are described.Type: GrantFiled: March 16, 2000Date of Patent: August 31, 2010Assignee: Sanofi Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Patent number: 7749518Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.Type: GrantFiled: May 16, 2005Date of Patent: July 6, 2010Assignee: Novartis Vaccines and Diagnostics SRLInventors: Vega Masignani, Beatrice Maria Arico
-
Publication number: 20100150967Abstract: There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae (NTHi) vaccine. The vaccine is typically an oral whole killed NTHi vaccine.Type: ApplicationFiled: March 14, 2008Publication date: June 17, 2010Applicant: Hunter Immunology LimitedInventors: Margaret Dunkley, Robert Clancy, Allan William Cripps, Diana Christine Otczyk
-
Publication number: 20100112078Abstract: The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wherein surprisingly the nanoparticle induces cellular response and the microparticle induces humoral response. The invention further provides a method of inducing cellular and/or humoral immune response.Type: ApplicationFiled: September 25, 2009Publication date: May 6, 2010Applicant: NATIONAL INSTITUTE OF IMMUNOLOGYInventors: Amulya K. Panda, Kanchan Vibhu
-
Publication number: 20100074922Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.Type: ApplicationFiled: September 30, 2009Publication date: March 25, 2010Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Publication number: 20100028448Abstract: Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism.Type: ApplicationFiled: October 5, 2009Publication date: February 4, 2010Applicant: ARTIFICIAL CELL TECHNOLOGIES, INC.Inventor: Donald T. Haynie
-
Patent number: 7641906Abstract: The invention relates to intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis.Type: GrantFiled: October 27, 2005Date of Patent: January 5, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Xin-Xing Gu
-
Publication number: 20090297559Abstract: The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pulmonary mucosa.Type: ApplicationFiled: July 6, 2009Publication date: December 3, 2009Inventors: Alessio FASANO, Blake Paterson
-
Patent number: RE41277Abstract: A novel surface exposed protein of Haemophilus influenzae or related Haemophilus species is described. The protein named protein D is an Ig receptor for human IgD and has an apparent molecular weight of 42,000. Protein D can be detected in all of 116 encapsulated and non-encapsulated isolates of H. influenzae studied. The protein from all strains shows in addition to the same apparent molecular weight immunogenic similarities since protein D from all strains interacts with three different mouse monoclonal antibodies and monoclonal human IgD. A method for purification of protein D is described. Cloning of the protein D gene from H. influenzae in E. coli is described as well as the nucleotide sequence and the deduced amino acid sequence.Type: GrantFiled: October 2, 2008Date of Patent: April 27, 2010Inventor: Arne Forsgren